DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA

拟议研究的目的是发展设计能力， 急性髓细胞白血病患者的个体化治疗方案 白血病（AML）。 为此，关于以下患者的临床特征的数据 急性髓细胞白血病患者正在收集，使患者的生存能力 可以估计强化缓解诱导治疗。 先前 未经治疗的患者正在接受标准合作组的治疗， 方案，而复发患者正在接受统一的治疗， 协议. 治疗前白血病细胞体外药物敏感性研究及 将进行所有周期研究，以评估分析的有效性 这对于预测响应可能是有用的。 类似地 治疗期间的系列骨髓检查和血浆测量 将进行治疗期间达到的药物水平，以促进 开发对治疗反应进行早期评估的方法 在进行治疗的同时

The purpose of the proposed studies is to develop the ability to design individualized treatment regimens for patients with acute myelocytic leukemia (AML). To this end data regarding the clinical characteristics of AML patients is being collected so that the ability of patients to survive intensive remission induction therapy can be estimated. Previously untreated patients are being treated with the standard cooperative group protocols while relapsed patients are being uniformly treated on common protocols. Pretherapy in vitro leukemic cell drug sensitivity studies and all cycle studies will be carried out to assess the usefulness of assays which would be potentially useful for predicting response. Similarly serial bone marrow examinations during therapy and measurements of plasma drug levels achieved during therapy will be carried out to facilitate development of the means to make an early assessment of response to therapy while therapy is being administered.